Ottawa Regional Cancer Foundation - Academic Profile

Publications

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

M. Brada , Khê Hoang‐Xuan , R. Rampling +13 more

Recurrent glioblastoma multiforme (GBM) is resistant to most therapeutic endeavors, with low response rates and survival rarely exceeding six months. There are no clearly establ...

2001 Annals of Oncology 367 citations

Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review

Fatma Ataman , Philip Poortmans , Roger Stupp +2 more

The phase III randomised European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trail Group (NCIC) Intergroup trial ...

2004 European Journal of Cancer 36 citations

Affiliated Researchers

David Macdonald

Ottawa Regional Cancer Foundation

Institution Info

Type: nonprofit
Country: CA
Publications: 2
Citations: 403

External Links

Identifiers

ROR: https://ror.org/01z89mt14